Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer
Gastric Cancer
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
The standard form of curative therapy for gastric cancer is radical surgery. However, the incidences of local failure in the tumor bed and regional lymph nodes, and distant failures via hematogenous or peritoneal routes, remain high.[1] As such, comprehensive staging and evaluation with a multidisciplinary team to determine roles of neoadjuvant, perioperative, and adjuvant combination chemotherapy, surgery, and external-beam radiation therapies should be considered.
Sources: 1
Investigators in Europe evaluated the role of perioperative chemotherapy without radiation therapy.[2] Initially, in a randomized phase III trial (MRC-ST02 [NCT00002615]), patients with stage II or higher adenocarcinoma of the stomach or of the lower third of the esophagus were assigned to receive three cycles of epirubicin, cisplatin, and continuous infusion fluorouracil (5-FU) (ECF) before and after surgery or to receive surgery alone. Compared with the surgery group, the perioperative chemotherapy group had a significantly higher overall survival (OS) (hazard ratio [HR]death, 0.75; 95% confidence interval [CI], 0.60–0.93; P = .009).[2][Level of evidence A1]
Sources: 2 · MRC-ST02 · 2 · Level of evidence A1
In addition, in the randomized phase III AIO-FLOT4 trial (NCT01216644), patients with resectable disease that was stage T2 or higher and/or node positive received either perioperative epirubicin, cisplatin, and 5-FU or capecitabine (ECF/ECX) (three cycles before and after surgery) or perioperative docetaxel, oxaliplatin, and 5-FU/leucovorin (FLOT) (four 2-week cycles before and after surgery). OS was significantly prolonged from 35 months with ECF/ECX to 50 months with FLOT (HR, 0.77; 95% CI, 0.63–0.94; P = .012).[3]
In a phase III Intergroup trial (SWOG-9008 [NCT01197118]), 559 patients with completely resected stage IB to stage IV (M0) adenocarcinoma of the stomach and gastroesophageal junction were randomly assigned to receive either surgery alone or surgery plus postoperative chemotherapy (5-FU and leucovorin) and concurrent radiation therapy (45 Gy). With a median follow-up of more than 10 years, a significant survival benefit was reported for patients who received adjuvant combined modality therapy.[4][Level of evidence A1] Median OS was 35 months for the adjuvant chemoradiation therapy group and 27 months for the surgery-alone arm (P = .0046). Median relapse-free survival was 27 months in the chemoradiation arm compared with 19 months in the surgery-alone arm (P < .001).
Sources: SWOG-9008 · 4 · Level of evidence A1
Gastroesophageal junction cancers may be treated like esophageal cancers and are best managed under the care of a multidisciplinary team. For more information, see Esophageal Cancer Treatment.
Sources: Esophageal Cancer Treatment
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[5,6] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[5-7] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[8-10] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[11] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[12]
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment options for stage 0 gastric cancer include:
Sources: stage 0 gastric cancer
Surgery.
Sources: Surgery
Endoscopic mucosal resection (EMR).
Sources: Endoscopic mucosal resection (EMR)
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Stage 0 is gastric cancer confined to mucosa. Experience in Japan, where stage 0 is diagnosed frequently, indicates that more than 90% of patients treated by gastrectomy with lymphadenectomy survive beyond 5 years. An American series confirmed these results.[1]
Sources: 1
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
EMR has been studied in Japan and throughout Asia in patients with early-stage tumors with good-risk features (Tis or T1a, diameter ≤2 cm, predominantly differentiated type, without ulcerative findings) that have a lower risk of nodal metastasis. Intramucosal tumors have a lower risk of nodal metastasis than submucosal tumors.[2] Careful patient selection according to risk criteria, treatment with an experienced endoscopist, and close surveillance should be considered.
Sources: 2
Evidence (EMR):
A prospective trial of EMR included 445 patients with intramucosal carcinoma (a total of 479 tumors) treated in Tokyo between 1987 and 1998. Complete resection was recommended for patients with evidence of submucosal invasion, blood vessel involvement, and/or positive margins.[3][Level of evidence C2]
Sources: 3 · Level of evidence C2
A prospective trial of EMR included 445 patients with intramucosal carcinoma (a total of 479 tumors) treated in Tokyo between 1987 and 1998. Complete resection was recommended for patients with evidence of submucosal invasion, blood vessel involvement, and/or positive margins.[3][Level of evidence C2]
Of the 405 patients with intramucosal disease, 278 underwent complete resection, with 2% local recurrence treated with curative intent and 100% disease-free survival at a median follow-up of 38 months.
In those with resections that were incomplete or not evaluable, 18 of 127 patients had a local recurrence and underwent curative surgery.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment options for stage I gastric cancer include:
Sources: stage I gastric cancer
Surgical resection with one of the following procedures:Regional lymphadenectomy is recommended with all of the above procedures. Splenectomy is not routinely performed.[1]
Sources: Surgical resection · 1
Surgical resection with one of the following procedures:Regional lymphadenectomy is recommended with all of the above procedures. Splenectomy is not routinely performed.[1]
Distal subtotal gastrectomy (if the lesion is not in the fundus or at the cardioesophageal junction).
Proximal subtotal gastrectomy or total gastrectomy, both with distal esophagectomy (if the lesion involves the cardia). These tumors often involve the submucosal lymphatics of the esophagus.
Total gastrectomy (if the tumor involves the stomach diffusely or arises in the body of the stomach and extends to within 6 cm of the cardia or distal antrum).
Endoscopic mucosal resection (EMR) for select patients with stage IA gastric cancer.
Sources: Endoscopic mucosal resection (EMR)
Postoperative chemoradiation therapy or perioperative chemotherapy for patients with node-positive (T1 N1) and muscle-invasive (T2 N0) disease.[2,3]
Sources: Postoperative chemoradiation therapy · perioperative chemotherapy · 2 · 3
Neoadjuvant chemoradiation (under clinical evaluation).[4]
Sources: 4
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Surgical resection including regional lymphadenectomy is the treatment of choice for patients with stage I gastric cancer.[1] If the lesion is not in the cardioesophageal junction and does not diffusely involve the stomach, subtotal gastrectomy is the procedure of choice, because it has demonstrated equivalent survival when compared with total gastrectomy and is associated with decreased morbidity.[5][Level of evidence A1] When the lesion involves the cardia, proximal subtotal gastrectomy or total gastrectomy (including a sufficient length of esophagus) may be performed with curative intent. If the lesion diffusely involves the stomach, total gastrectomy is required. At a minimum, surgical resection includes greater and lesser curvature perigastric regional lymph nodes. In patients with stage I gastric cancer, perigastric lymph nodes may contain cancer.
Sources: 1 · 5 · Level of evidence A1
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
EMR has been studied in Japan and throughout Asia in patients with early-stage tumors with good-risk features (Tis or T1a, diameter ≤2 cm, predominantly differentiated type, without ulcerative findings) that have a lower risk of nodal metastasis. Intramucosal tumors have a lower risk of nodal metastasis than submucosal tumors.[6] Careful patient selection according to risk criteria, treatment with an experienced endoscopist, and close surveillance should be considered.
Sources: 6
Evidence (EMR):
A prospective trial of EMR included 445 patients with intramucosal carcinoma (a total of 479 tumors) treated in Tokyo between 1987 and 1998. Complete resection was recommended for patients with evidence of submucosal invasion, blood vessel involvement, and/or positive margins.[7][Level of evidence C2]
Sources: 7 · Level of evidence C2
A prospective trial of EMR included 445 patients with intramucosal carcinoma (a total of 479 tumors) treated in Tokyo between 1987 and 1998. Complete resection was recommended for patients with evidence of submucosal invasion, blood vessel involvement, and/or positive margins.[7][Level of evidence C2]
Of the 405 patients with intramucosal disease, 278 underwent complete resection, with 2% local recurrence treated with curative intent and 100% disease-free survival at a median follow-up of 38 months.
In those with resections that were incomplete or not evaluable, 18 of 127 patients had a local recurrence and underwent curative surgery.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Patients with node-positive (T1 N1) and muscle-invasive (T2 N0) disease may consider postoperative chemoradiation therapy.
Evidence (postoperative chemoradiation therapy):
A prospective, multi-institution, phase III trial (SWOG-9008 [NCT01197118]) evaluated postoperative combined chemoradiation therapy versus surgery alone in 559 patients with completely resected stage IB to stage IV (M0) adenocarcinoma of the stomach and gastroesophageal junction. There was a significant survival benefit with adjuvant combined modality therapy.[2][Level of evidence A1] Because the prognosis is relatively favorable for patients with completely resected stage IB disease, the effectiveness of adjuvant chemoradiation therapy for this group is less clear.
Sources: SWOG-9008 · 2 · Level of evidence A1
A prospective, multi-institution, phase III trial (SWOG-9008 [NCT01197118]) evaluated postoperative combined chemoradiation therapy versus surgery alone in 559 patients with completely resected stage IB to stage IV (M0) adenocarcinoma of the stomach and gastroesophageal junction. There was a significant survival benefit with adjuvant combined modality therapy.[2][Level of evidence A1] Because the prognosis is relatively favorable for patients with completely resected stage IB disease, the effectiveness of adjuvant chemoradiation therapy for this group is less clear.
With more than 10 years of follow-up, median survival was 35 months for the adjuvant chemoradiation therapy group and 27 months for the surgery-alone arm (P = .0046).
Median relapse-free survival was 27 months in the chemoradiation arm compared with 19 months in the surgery-alone arm (P < .001). Improvement was primarily seen for locoregional recurrence risk (improvement from 47% for surgery vs. 29% for chemoradiation).[2] However, only 36 patients in the trial had stage IB tumors (18 patients in each arm).[8]
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Investigators in Europe evaluated the role of perioperative chemotherapy without radiation therapy.[9]
Sources: 9
Evidence (perioperative chemotherapy):
In the randomized phase III AIO-FLOT4 trial (NCT01216644), 716 patients with stage IB to stage III resectable gastric or gastroesophageal adenocarcinoma were randomly assigned to receive either perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil (5-FU)/leucovorin (FLOT); or epirubicin, cisplatin, and 5-FU or capecitabine (ECF/ECX).[3][Level of evidence A1]
Sources: AIO-FLOT4 · 3 · Level of evidence A1
In the randomized phase III AIO-FLOT4 trial (NCT01216644), 716 patients with stage IB to stage III resectable gastric or gastroesophageal adenocarcinoma were randomly assigned to receive either perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil (5-FU)/leucovorin (FLOT); or epirubicin, cisplatin, and 5-FU or capecitabine (ECF/ECX).[3][Level of evidence A1]
Median overall survival was 50 months with FLOT and 35 months with ECF/ECX (hazard ratio, 0.77; 95% confidence interval, 0.63–0.94; P = .012).
Margin-free resection in the FLOT group was 85% versus 78% in the ECF/ECX group (P = .0162).
Toxicity rates were similar between groups (26% required hospitalizations in the ECF/ECX group and 25% in the FLOT group). However, types of side effects differed, with increased nausea, thromboembolic events, and anemia in the ECF/ECX group versus higher rates of grade 3/4 infections, neutropenia, diarrhea, and neuropathy in the FLOT group.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment options for stage II gastric cancer and stage III gastric cancer include:
Sources: stage II gastric cancer · stage III gastric cancer
Surgical resection (after discussion with a multidisciplinary team regarding the role of perioperative and adjuvant therapy) may include one of the following procedures:Regional lymphadenectomy is recommended with all of the above procedures. Splenectomy is not routinely performed.[1]
Sources: Surgical resection · 1
Surgical resection (after discussion with a multidisciplinary team regarding the role of perioperative and adjuvant therapy) may include one of the following procedures:Regional lymphadenectomy is recommended with all of the above procedures. Splenectomy is not routinely performed.[1]
Distal subtotal gastrectomy (if the lesion is not in the fundus or at the cardioesophageal junction).
Proximal subtotal gastrectomy or total gastrectomy (if the lesion involves the cardia).
Total gastrectomy (if the tumor involves the stomach diffusely or arises in the body of the stomach and extends to within 6 cm of the cardia).
Perioperative chemotherapy.[2]
Sources: Perioperative chemotherapy · 2
Postoperative (adjuvant) chemoradiation therapy.[3]
Sources: Postoperative (adjuvant) chemoradiation therapy · 3
Postoperative (adjuvant) chemotherapy.
Neoadjuvant chemoradiation therapy (under clinical evaluation).[4]
Sources: 4
Perioperative chemotherapy and immunotherapy regimens (under clinical evaluation).
No randomized trials of adjuvant chemoradiation versus perioperative chemotherapy have been undertaken.
All newly diagnosed patients with stages II and III gastric cancer should consider clinical trials.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Because of the high risk of locoregional and distant recurrence, perioperative and postoperative therapy should be considered in addition to surgery.
Surgical resection with regional lymphadenectomy is the treatment of choice for patients with stages II and III gastric cancer; all eligible patients undergo surgery.[1] If the lesion is not in the cardioesophageal junction and does not diffusely involve the stomach, subtotal gastrectomy is the procedure of choice. When the lesion involves the cardia, proximal subtotal gastrectomy or total gastrectomy may be performed with curative intent. If the lesion diffusely involves the stomach, total gastrectomy and appropriate lymph node resection may be required. The role of extended lymph node (D2) dissection is uncertain [5] and in some series is associated with increased morbidity.[6,7] As many as 15% of selected stage III patients can be cured by surgery alone, particularly if lymph node involvement is minimal (<7 lymph nodes).
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Investigators in Europe evaluated the role of perioperative chemotherapy without radiation therapy.[2]
Sources: 2
Evidence (perioperative chemotherapy):
In the randomized phase III AIO-FLOT4 trial (NCT01216644), 716 patients with stage IB to stage III resectable gastric or gastroesophageal adenocarcinoma were randomly assigned to receive either perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil (5-FU)/leucovorin (FLOT) or epirubicin, cisplatin, and 5-FU or capecitabine (ECF/ECX).[8][Level of evidence A1]
Sources: AIO-FLOT4 · 8 · Level of evidence A1
In the randomized phase III AIO-FLOT4 trial (NCT01216644), 716 patients with stage IB to stage III resectable gastric or gastroesophageal adenocarcinoma were randomly assigned to receive either perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil (5-FU)/leucovorin (FLOT) or epirubicin, cisplatin, and 5-FU or capecitabine (ECF/ECX).[8][Level of evidence A1]
Median overall survival (OS) was 50 months with FLOT and 35 months with ECF/ECX (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.63–0.94; P = .012).
Margin-free resection in the FLOT group was 85% versus 78% in the ECF/ECX group (P = .0162).
Toxicity rates were similar between groups (26% required hospitalizations in the ECF/ECX group and 25% in the FLOT group). However, types of side effects differed, with increased nausea, thromboembolic events, and anemia in the ECF/ECX group versus higher rates of grade 3/4 infections, neutropenia, diarrhea, and neuropathy in the FLOT group.
In the randomized phase III MAGIC trial (NCT00002615), patients with stage II or higher adenocarcinoma of the stomach or of the lower third of the esophagus were assigned to receive three cycles of epirubicin, cisplatin, and continuous infusion 5-FU (ECF) before and after surgery or to receive surgery alone.[2]
In the randomized phase III MAGIC trial (NCT00002615), patients with stage II or higher adenocarcinoma of the stomach or of the lower third of the esophagus were assigned to receive three cycles of epirubicin, cisplatin, and continuous infusion 5-FU (ECF) before and after surgery or to receive surgery alone.[2]
Compared with the surgery group, the perioperative chemotherapy group had a significantly higher likelihood of progression-free survival (HRprogression, 0.66; 95% CI, 0.53–0.81; P < .001) and of OS (HRdeath, 0.75; 95% CI, 0.60–0.93; P = .009).
The 5-year OS rate was 36.3% (95% CI, 29.5%‒43.0%) for the perioperative chemotherapy group and 23% (95% CI, 16.6%‒29.4%) for the surgery group.[2][Level of evidence A1]
Sources: 2 · Level of evidence A1
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Patients with stages II and III gastric cancer who have not received neoadjuvant therapy may consider postoperative chemoradiation therapy.
Evidence (postoperative [adjuvant] chemoradiation therapy):
A prospective, multi-institution, phase III trial (SWOG-9008 [NCT01197118]) evaluated postoperative combined chemoradiation therapy compared with surgery alone in 559 patients with completely resected stage IB to stage IV (M0) adenocarcinoma of the stomach and gastroesophageal junction. Investigators reported a significant survival benefit for patients who received adjuvant combined-modality therapy.[3][Level of evidence A1]
Sources: SWOG-9008 · 3 · Level of evidence A1
A prospective, multi-institution, phase III trial (SWOG-9008 [NCT01197118]) evaluated postoperative combined chemoradiation therapy compared with surgery alone in 559 patients with completely resected stage IB to stage IV (M0) adenocarcinoma of the stomach and gastroesophageal junction. Investigators reported a significant survival benefit for patients who received adjuvant combined-modality therapy.[3][Level of evidence A1]
With more than 10 years of follow-up, median survival was 35 months for the adjuvant chemoradiation therapy arm and 27 months for the surgery-alone arm (P = .0046).
Median relapse-free survival was 27 months in the chemoradiation arm compared with 19 months in the surgery-alone arm (P < .001). Improvement was primarily seen for locoregional recurrence risk (improvement from 47% for surgery vs. 29% for chemoradiation).[3] However, only 36 patients in the trial had stage IB tumors (18 patients in each arm).[9]
Attempts to evaluate the role of more intensive chemotherapy regimens in combination with radiation in the Cancer and Leukemia Group B study (CALGB-80101 [NCT00052910]) demonstrated no survival benefit. The 546 patients who had undergone curative resection of stage IB to stage IV (M0) gastric or gastroesophageal junction adenocarcinoma received postoperative 5-FU with leucovorin before and after radiation or postoperative ECF before and after combined radiation therapy.[10]
Sources: CALGB-80101 · 10
Attempts to evaluate the role of more intensive chemotherapy regimens in combination with radiation in the Cancer and Leukemia Group B study (CALGB-80101 [NCT00052910]) demonstrated no survival benefit. The 546 patients who had undergone curative resection of stage IB to stage IV (M0) gastric or gastroesophageal junction adenocarcinoma received postoperative 5-FU with leucovorin before and after radiation or postoperative ECF before and after combined radiation therapy.[10]
The 5-year OS rate was 44% in both arms.
In a phase III Dutch trial (CRITICS [NCT00407186]), 788 patients with stage IB to stage IVA gastric/gastroesophageal junction adenocarcinoma received preoperative chemotherapy and surgery, and then were randomly assigned to receive postoperative chemotherapy or chemoradiotherapy.[11] Adjuvant chemoradiation did not improve survival in those who received neoadjuvant chemotherapy.
In a phase III Dutch trial (CRITICS [NCT00407186]), 788 patients with stage IB to stage IVA gastric/gastroesophageal junction adenocarcinoma received preoperative chemotherapy and surgery, and then were randomly assigned to receive postoperative chemotherapy or chemoradiotherapy.[11] Adjuvant chemoradiation did not improve survival in those who received neoadjuvant chemotherapy.
Median OS was 43 months in the chemotherapy arm and 37 months in the chemoradiotherapy group (95% CI, 0.84–1.22; P = .90).
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Investigators in Europe evaluated the role of postoperative chemotherapy without radiation therapy.[2]
Sources: 2
Evidence (postoperative [adjuvant] chemotherapy):
Japanese investigators randomly assigned 1,059 patients with stage II or III gastric cancer who had undergone a D2 gastrectomy to receive either 1 year of S-1, an oral fluoropyrimidine not available in the United States, or follow-up after surgery alone.[12] Patients were randomly assigned in a 1:1 fashion.
Sources: 12
Japanese investigators randomly assigned 1,059 patients with stage II or III gastric cancer who had undergone a D2 gastrectomy to receive either 1 year of S-1, an oral fluoropyrimidine not available in the United States, or follow-up after surgery alone.[12] Patients were randomly assigned in a 1:1 fashion.
The 3-year OS rate was 80.1% in the S-1 group and 70.1% in the surgery-only group. The HRdeath in the S-1 group, as compared with the surgery-only group, was 0.68 (95% CI, 0.52–0.87; P = .003).[12][Level of evidence A1]
Sources: 12 · Level of evidence A1
Investigators in Asia evaluated the role of capecitabine/oxaliplatin as adjuvant therapy after gastric cancer resection. In the CLASSIC trial (NCT00411229), 37 centers in South Korea, China, and Taiwan randomly assigned 1,035 patients with stages IIA, IIB, IIIA, or IIIB gastric cancer who had undergone a curative D2 gastrectomy to receive either adjuvant chemotherapy (eight 3-week cycles of capecitabine plus oxaliplatin) or follow-up alone after surgery.[13]
Investigators in Asia evaluated the role of capecitabine/oxaliplatin as adjuvant therapy after gastric cancer resection. In the CLASSIC trial (NCT00411229), 37 centers in South Korea, China, and Taiwan randomly assigned 1,035 patients with stages IIA, IIB, IIIA, or IIIB gastric cancer who had undergone a curative D2 gastrectomy to receive either adjuvant chemotherapy (eight 3-week cycles of capecitabine plus oxaliplatin) or follow-up alone after surgery.[13]
The 3-year disease-free survival rate was 74% in the chemotherapy group and 59% in the surgery-alone group (HR, 0.56; 95% CI, 0.44–0.72; P < .0001).
The 3-year OS rate was 83% in the chemotherapy group and 78% in the surgery-alone group (HR, 0.72; 95% CI, 0.52–1.00; P = .0493).[13][Level of evidence A1]
Sources: 13 · Level of evidence A1
Further follow-up is anticipated.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment options for stage IV, inoperable, and recurrent gastric cancer, including patients with medically or surgically unresectable disease, include a combination of cytotoxic therapies, targeted therapies, immunotherapies, and palliative locoregional therapies.
Patients with metastatic gastric adenocarcinoma should consider undergoing testing for HER2 amplification, defective mismatch repair (dMMR) (immunohistochemistry [IHC] staining), or microsatellite instability (MSI) (polymerase chain reaction), along with programmed death ligand 1 (PD-L1) combined positive score (CPS score in the United States).
First-line palliative systemic therapy for patients with HER2-negative tumors.
First-line palliative systemic therapy for patients with HER2-negative tumors.
Palliative chemotherapy with or without immunotherapy.
Sources: Palliative chemotherapy
First-line palliative systemic therapy for patients with HER2-negative tumors. › Palliative chemotherapy with or without immunotherapy.
Chemotherapy with immunotherapy: fluorouracil (5-FU) or capecitabine combined with oxaliplatin and nivolumab.
First-line palliative systemic therapy for patients with HER2-negative tumors.
Monoclonal antibody therapy with chemotherapy for patients with CLDN18.2-positive tumors.
Sources: Monoclonal antibody therapy with chemotherapy for patients with CLDN18.2-positive tumors
First-line palliative systemic therapy for patients with HER2-negative tumors. › Monoclonal antibody therapy with chemotherapy for patients with CLDN18.2-positive tumors.
Zolbetuximab plus CAPOX (capecitabine and oxaliplatin) or mFOLFOX6 (modified leucovorin [or levoleucovorin], 5-FU, and oxaliplatin).[1,2]
Sources: Zolbetuximab plus CAPOX (capecitabine and oxaliplatin) or mFOLFOX6 (modified leucovorin [or levoleucovorin], 5-FU, and oxaliplatin) · 1 · 2
First-line palliative systemic therapy for patients with HER2-negative tumors.
Triplet regimens.
First-line palliative systemic therapy for patients with HER2-negative tumors. › Triplet regimens.
5-FU combined with either epirubicin and cisplatin, etoposide and leucovorin, doxorubicin and methotrexate, leucovorin and irinotecan, or docetaxel and cisplatin or oxaliplatin.[3-9]
First-line palliative systemic therapy for patients with HER2-negative tumors.
Doublet regimens.
First-line palliative systemic therapy for patients with HER2-negative tumors. › Doublet regimens.
A taxane (docetaxel or paclitaxel) and either cisplatin or carboplatin.
5-FU and cisplatin.
CAPOX.[10]
Sources: 10
First-line palliative systemic therapy for patients with HER2-negative tumors.
Single agents.
First-line palliative systemic therapy for patients with HER2-negative tumors. › Single agents.
5-FU or capecitabine.[11,12]
A taxane (either docetaxel or paclitaxel).
First-line palliative systemic therapy for patients with HER2-positive tumors (3+ on IHC or 2+ on IHC with a positive fluorescence in situ hybridization [FISH]).
First-line palliative systemic therapy for patients with HER2-positive tumors (3+ on IHC or 2+ on IHC with a positive fluorescence in situ hybridization [FISH]).
Immunotherapy with chemotherapy.
Sources: Immunotherapy with chemotherapy
First-line palliative systemic therapy for patients with HER2-positive tumors (3+ on IHC or 2+ on IHC with a positive fluorescence in situ hybridization [FISH]). › Immunotherapy with chemotherapy.
Nivolumab with chemotherapy.
Sources: Nivolumab with chemotherapy
Trastuzumab with chemotherapy.
Sources: Trastuzumab with chemotherapy
Second-line palliative systemic therapy.
Ramucirumab with or without chemotherapy.
Pembrolizumab for patients with dMMR or MSI-high (MSI-H) tumors.
Sources: Pembrolizumab
Trastuzumab deruxtecan for patients with HER2-positive tumors (3+ on IHC or 2+ on IHC with a positive FISH).
Sources: Trastuzumab deruxtecan
Third-line palliative systemic therapy.
Third-line palliative systemic therapy.
Trifluridine and tipiracil.
Sources: Trifluridine and tipiracil
Endoluminal laser therapy, endoluminal stent placement, or gastrojejunostomy may be helpful to patients with gastric obstruction.[13]
Sources: 13
Palliative radiation therapy may alleviate bleeding, pain, and obstruction.
Palliative resection is reserved for patients with continued bleeding or obstruction.
Regorafenib with nivolumab (under clinical evaluation).
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (under clinical evaluation).
Treatment with poly (ADP-ribose) polymerase (PARP) inhibitors and hepatocyte growth factor inhibitors have not shown efficacy at this time, but combination studies are under way.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Standard chemotherapy versus best supportive care for patients with metastatic gastric cancer has been tested in several clinical trials, and there is general agreement that patients who receive chemotherapy live for several months longer on average than patients who receive supportive care.[14-16][Level of evidence A1] During the last 20 years, multiple randomized studies evaluating different treatment regimens (monotherapy vs. combination [doublet and triplet] chemotherapy) have been performed in patients with metastatic gastric cancer with no clear consensus as to the best management approach. A meta-analysis of these studies demonstrated a hazard ratio (HR) of 0.83 for overall survival (OS) (95% confidence interval [CI], 0.74–0.93) in favor of combination chemotherapy.[17] The addition of immune checkpoint inhibitors to oxaliplatin-based chemotherapy has shown further OS benefit.
Sources: 14 · 16 · Level of evidence A1 · 17
Evidence (palliative chemotherapy):
Of all the combination regimens, epirubicin, cisplatin, and 5-FU (ECF) is often considered the reference standard in the United States and Europe. In one European trial, 274 patients with metastatic esophagogastric cancer were randomly assigned to receive either ECF or 5-FU, doxorubicin, and methotrexate (FAMTX).[18]
Sources: 18
Of all the combination regimens, epirubicin, cisplatin, and 5-FU (ECF) is often considered the reference standard in the United States and Europe. In one European trial, 274 patients with metastatic esophagogastric cancer were randomly assigned to receive either ECF or 5-FU, doxorubicin, and methotrexate (FAMTX).[18]
The group who received ECF had a significantly longer median survival (8.9 vs. 5.7 months, P = .0009) than the FAMTX group.[18][Level of evidence A1]
Sources: 18 · Level of evidence A1
In a second trial that compared ECF with mitomycin, cisplatin, and 5-FU (MCF), there was no statistically significant difference in median survival (9.4 vs. 8.7 months, P = .315).[4][Level of evidence A1]
Sources: 4 · Level of evidence A1
Oxaliplatin or capecitabine are often substituted for cisplatin and 5-FU within the ECF regimen on the basis of results from the REAL-2 trial (ISRCTN51678883).[10] This randomized trial of 1,002 patients with advanced esophageal, gastroesophageal junction, or gastric cancer utilized a 2 × 2 design.
Sources: ISRCTN51678883 · 10
Oxaliplatin or capecitabine are often substituted for cisplatin and 5-FU within the ECF regimen on the basis of results from the REAL-2 trial (ISRCTN51678883).[10] This randomized trial of 1,002 patients with advanced esophageal, gastroesophageal junction, or gastric cancer utilized a 2 × 2 design.
The trial demonstrated noninferior median OS in patients treated with capecitabine rather than 5-FU (HRdeath, 0.86; 95% CI, 0.82–0.99) and in patients treated with oxaliplatin in place of cisplatin (HRdeath, 0.92; 95% CI, 0.80–1.10)
An international collaboration of investigators randomly assigned 445 patients with metastatic gastric cancer to receive docetaxel, cisplatin, and 5-FU (DCF) or cisplatin and 5-FU.[19] Time-to-treatment progression (TTP) was the primary end point.
Sources: 19
An international collaboration of investigators randomly assigned 445 patients with metastatic gastric cancer to receive docetaxel, cisplatin, and 5-FU (DCF) or cisplatin and 5-FU.[19] Time-to-treatment progression (TTP) was the primary end point.
Patients who received DCF experienced a significantly longer TTP (5.6 months; 95% CI, 4.9–5.9; vs. 3.7 months; 95% CI, 3.4–4.5; HR, 1.47; 95% CI, 1.19–1.82; log-rank P < .001; risk reduction, 32%).
The median OS was significantly longer for patients who received DCF compared with patients who received cisplatin and 5-FU (9.2 months; 95% CI, 8.4–10.6; vs. 8.6 months; 95% CI, 7.2–9.5; HR, 1.29; 95% CI, 1.0–1.6; log-rank P = .02; risk reduction, 23%).[19][Level of evidence A1]
Sources: 19 · Level of evidence A1
The toxicity rates were high in both arms.[20]
Sources: 20
Febrile neutropenia was more common in patients who received DCF (29% vs. 12%). The death rate was 10.4% in patients who received DCF and 9.4% in patients who received cisplatin and 5-FU.
It is unclear if cisplatin and 5-FU should be considered as an index regimen for the treatment of patients with metastatic gastric cancer.[20] The results of a study that randomly assigned 245 patients with metastatic gastric cancer to receive cisplatin and 5-FU, FAMTX, or etoposide, leucovorin, and 5-FU (ELF) demonstrated no significant difference in response rate, progression-free survival (PFS), or OS between the arms.[5]
It is unclear if cisplatin and 5-FU should be considered as an index regimen for the treatment of patients with metastatic gastric cancer.[20] The results of a study that randomly assigned 245 patients with metastatic gastric cancer to receive cisplatin and 5-FU, FAMTX, or etoposide, leucovorin, and 5-FU (ELF) demonstrated no significant difference in response rate, progression-free survival (PFS), or OS between the arms.[5]
Grades 3 and 4 neutropenia occurred in 35% to 43% of patients on all arms, but severe nausea and vomiting was more common in patients in the cisplatin-and-5-FU arm and occurred in 26% of those patients.[5][Level of evidence B3]
Sources: 5 · Level of evidence B3
Phase II studies that evaluated irinotecan-based or oxaliplatin-based regimens demonstrated similar response rates and TTP to those reported in trials using ECF or cisplatin and 5-FU, but the former regimen may be less toxic.[21-26] There are conflicting data regarding relative efficacy of any one regimen.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Two randomized trials tested the addition of zolbetuximab to either CAPOX or mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative metastatic gastroesophageal or gastric adenocarcinoma.[1,2]
Evidence (zolbetuximab with chemotherapy):
In the phase III GLOW trial (NCT03653507), 507 patients were randomly assigned to receive CAPOX and either zolbetuximab or placebo.[1]
In the phase III GLOW trial (NCT03653507), 507 patients were randomly assigned to receive CAPOX and either zolbetuximab or placebo.[1]
The median PFS was 8.21 months in the zolbetuximab arm and 6.80 months in the placebo arm (HR, 0.687; 95% CI, 0.544–0.866; P = .0007). The median OS was 14.39 months in the zolbetuximab arm and 12.16 months in the placebo arm (HR, 0.771; 95% CI, 0.615–0.965; P = .0118).[1][Level of evidence B1]
Sources: 1 · Level of evidence B1
The phase III SPOTLIGHT trial (NCT03504397) included 565 patients with CLDN18.2-positive, HER2-negative metastatic gastroesophageal or gastric adenocarcinoma. Patients were randomly assigned to receive mFOLFOX6 and either zolbetuximab or placebo.[2]
The phase III SPOTLIGHT trial (NCT03504397) included 565 patients with CLDN18.2-positive, HER2-negative metastatic gastroesophageal or gastric adenocarcinoma. Patients were randomly assigned to receive mFOLFOX6 and either zolbetuximab or placebo.[2]
The median PFS was 10.61 months (95% CI, 8.90–12.48) in the zolbetuximab arm and 8.67 months (95% CI, 8.21–10.28) in the placebo arm (HR, 0.75; 95% CI, 0.60–0.94; P = .0066). Patients who received zolbetuximab had a reduced risk of death (HR, 0.75; 95% CI, 0.60–0.94; P = .0053).[2][Level of evidence A1]
Sources: 2 · Level of evidence A1
A subsequent combined analysis of the SPOTLIGHT and GLOW trials showed that the addition of zolbetuximab did not negatively affect health-related quality of life.[27]
Sources: 27
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Nivolumab may be considered in combination with chemotherapy for patients with advanced or metastatic gastric cancer regardless of PD-L1 CPS status.[28]
Sources: 28
Evidence (nivolumab with chemotherapy):
In a randomized, open-label, international, phase III study (CheckMate-649 [NCT02872116]), patients with HER2-negative gastric or gastroesophageal junction adenocarcinomas were randomly assigned 1:1:1 to receive either nivolumab with chemotherapy (nivolumab 360 mg with CAPOX every 3 weeks or nivolumab 240 mg with leucovorin, 5-FU, and oxaliplatin [FOLFOX] every 2 weeks), chemotherapy alone (CAPOX every 3 weeks or FOLFOX every 2 weeks), or nivolumab 1 mg/kg and ipilimumab 3 mg/kg every 3 weeks × 4 (followed by maintenance nivolumab). The trial randomly assigned 1,581 patients (including 955 with PD-L1 CPS ≥5) to the chemotherapy-plus-nivolumab arm (n = 789; n = 473 with PD-L1 CPS ≥5) or the chemotherapy-alone arm (n = 792; n = 482 with PD-L1 CPS ≥5).[28]
Sources: CheckMate-649 · 28
In a randomized, open-label, international, phase III study (CheckMate-649 [NCT02872116]), patients with HER2-negative gastric or gastroesophageal junction adenocarcinomas were randomly assigned 1:1:1 to receive either nivolumab with chemotherapy (nivolumab 360 mg with CAPOX every 3 weeks or nivolumab 240 mg with leucovorin, 5-FU, and oxaliplatin [FOLFOX] every 2 weeks), chemotherapy alone (CAPOX every 3 weeks or FOLFOX every 2 weeks), or nivolumab 1 mg/kg and ipilimumab 3 mg/kg every 3 weeks × 4 (followed by maintenance nivolumab). The trial randomly assigned 1,581 patients (including 955 with PD-L1 CPS ≥5) to the chemotherapy-plus-nivolumab arm (n = 789; n = 473 with PD-L1 CPS ≥5) or the chemotherapy-alone arm (n = 792; n = 482 with PD-L1 CPS ≥5).[28]
For all patients (regardless of PD-L1 status), the median OS was 14.0 months (95% CI, 12.6–15.0) in the nivolumab-plus-chemotherapy arm compared with 11.3 months (95 % CI, 10.6–12.3) in the chemotherapy-alone arm (HR, 0.77; 99.3% CI, 0.64–0.92; P < .0001).
Patients with tumors with PD-L1 CPS greater than 5 had a median OS of 14.4 months (95% CI, 13.1–16.2) in the nivolumab-plus-chemotherapy arm compared with 11.1 months (95% CI, 10.0−12.1) in the chemotherapy-alone arm (HR, 0.71; 98.4% CI, 0.59–0.86; P = .0001).
Grades 3 and 4 adverse events occurred in 462 patients in the combination arm and in 341 patients in the chemotherapy-alone arm.[28][Level of evidence A1]
Sources: 28 · Level of evidence A1
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Trastuzumab may be combined with pembrolizumab and chemotherapy (either 5-FU and cisplatin or CAPOX) as treatment for patients with HER2-positive metastatic gastric adenocarcinoma. For patients who do not tolerate pembrolizumab, trastuzumab may be combined with cisplatin and 5-FU or capecitabine. HER2 testing is recommended for patients with metastatic disease.[29]
Sources: 29
Evidence (trastuzumab and pembrolizumab with chemotherapy):
The double-blind, placebo-controlled, phase III, international KEYNOTE-811 trial (NCT03615326) studied dual pembrolizumab, trastuzumab, and chemotherapy (either 5-FU with cisplatin or CAPOX). A total of 434 patients with metastatic HER2-positive gastric adenocarcinoma were randomly assigned in a 1:1 ratio to receive either chemotherapy and trastuzumab (6 mg/kg every 3 weeks) with or without pembrolizumab (200 mg intravenously [IV] every 3 weeks).
Sources: KEYNOTE-811
The double-blind, placebo-controlled, phase III, international KEYNOTE-811 trial (NCT03615326) studied dual pembrolizumab, trastuzumab, and chemotherapy (either 5-FU with cisplatin or CAPOX). A total of 434 patients with metastatic HER2-positive gastric adenocarcinoma were randomly assigned in a 1:1 ratio to receive either chemotherapy and trastuzumab (6 mg/kg every 3 weeks) with or without pembrolizumab (200 mg intravenously [IV] every 3 weeks).
The objective response rate at the first interim analysis was 74.4% (95% CI, 66.2%–81.6%) for patients in the pembrolizumab arm and 51.9% (95% CI, 43.0%–60.7%) for patients in the placebo arm.[29][Level of evidence B3]
Sources: 29 · Level of evidence B3
Adverse events grade 3 or higher were observed in 57.1% of patients in the pembrolizumab arm (including 33.6% of patients with immune-related reactions) and 57.4% of patients in the placebo arm.
Evidence (trastuzumab):
In the open-label, international, phase III Trastuzumab for Gastric Cancer trial (ToGA [NCT01041404]), patients with HER2-positive metastatic, inoperable locally advanced, or recurrent gastric or gastroesophageal junction cancer were randomly assigned to receive chemotherapy with or without the anti-HER2 monoclonal antibody trastuzumab.[30] HER2 positivity was defined as either 3+ by IHC or a HER2 to CEP17 ratio of 2 or more using FISH. Tumors from 3,665 patients were tested for HER2; of the patients, 810 were positive (22%) and 594 met eligibility criteria for randomization. Chemotherapy consisted of cisplatin plus 5-FU or capecitabine chosen at the investigator’s discretion. The study treatment was administered every 3 weeks for six cycles, and trastuzumab was continued every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent. Crossover to trastuzumab at disease progression was not permitted.
In the open-label, international, phase III Trastuzumab for Gastric Cancer trial (ToGA [NCT01041404]), patients with HER2-positive metastatic, inoperable locally advanced, or recurrent gastric or gastroesophageal junction cancer were randomly assigned to receive chemotherapy with or without the anti-HER2 monoclonal antibody trastuzumab.[30] HER2 positivity was defined as either 3+ by IHC or a HER2 to CEP17 ratio of 2 or more using FISH. Tumors from 3,665 patients were tested for HER2; of the patients, 810 were positive (22%) and 594 met eligibility criteria for randomization. Chemotherapy consisted of cisplatin plus 5-FU or capecitabine chosen at the investigator’s discretion. The study treatment was administered every 3 weeks for six cycles, and trastuzumab was continued every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent. Crossover to trastuzumab at disease progression was not permitted.
The median OS was 13.8 months (95% CI, 12–16) in patients assigned to trastuzumab and 11.1 months (95% CI, 10–13) in patients assigned to chemotherapy alone (HR, 0.74; 95% CI, 0.60–0.91; P = .0046).[30][Level of evidence A1]
Sources: 30 · Level of evidence A1
There was no significant difference in rates of any adverse event, and cardiotoxic effects were equally rare in both arms.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
The combination of pembrolizumab and chemotherapy has not shown superiority over chemotherapy alone.
Evidence (pembrolizumab with chemotherapy):
A phase III, partially blinded, randomized, international study (KEYNOTE-062 [NCT02494583]) of 763 patients with previously untreated advanced gastric cancer with a PD-L1 CPS of one or greater randomly assigned patients 1:1:1 to receive either pembrolizumab 200 mg IV every 3 weeks, pembrolizumab with chemotherapy (cisplatin with 5-FU or capecitabine), or chemotherapy alone.[31]
Sources: KEYNOTE-062 · 31
A phase III, partially blinded, randomized, international study (KEYNOTE-062 [NCT02494583]) of 763 patients with previously untreated advanced gastric cancer with a PD-L1 CPS of one or greater randomly assigned patients 1:1:1 to receive either pembrolizumab 200 mg IV every 3 weeks, pembrolizumab with chemotherapy (cisplatin with 5-FU or capecitabine), or chemotherapy alone.[31]
The final results did not show superiority of pembrolizumab or pembrolizumab with chemotherapy over chemotherapy alone.
However, when selected for a PD-L1 CPS of ten or greater, median OS was 17.4 months (95% CI, 9.1−23.1) in the pembrolizumab-alone arm compared with 10.8 months (95% CI, 8.5−13.8) in the chemotherapy-alone arm (HR, 0.69; 95% CI, 0.49−0.97). The prespecified statistical analysis plan did not test this difference further.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
There is no standard treatment option for patients who develop disease progression after first-line palliative chemotherapy. Accepted regimens include paclitaxel with or without ramucirumab, docetaxel, and irinotecan with or without 5-FU/leucovorin. Pembrolizumab is approved for the treatment of patients with dMMR or MSI-H tumors, and trastuzumab deruxtecan is approved for patients with HER2-positive gastric cancer.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Evidence (palliative chemotherapy):
Investigators in Korea randomly assigned patients with advanced gastric cancer who had previously received one or two chemotherapy regimens that involved both a fluoropyrimidine and a platinum agent to receive either salvage chemotherapy or best supportive care in a 2:1 fashion.[32] Salvage chemotherapy consisted of either docetaxel (60 mg/m2 every 3 weeks) or irinotecan (150 mg/m2 every 2 weeks) and was left to the discretion of the treating physicians. Of the 202 patients enrolled, 133 received salvage chemotherapy and 69 received best supportive care.
Sources: 32
Investigators in Korea randomly assigned patients with advanced gastric cancer who had previously received one or two chemotherapy regimens that involved both a fluoropyrimidine and a platinum agent to receive either salvage chemotherapy or best supportive care in a 2:1 fashion.[32] Salvage chemotherapy consisted of either docetaxel (60 mg/m2 every 3 weeks) or irinotecan (150 mg/m2 every 2 weeks) and was left to the discretion of the treating physicians. Of the 202 patients enrolled, 133 received salvage chemotherapy and 69 received best supportive care.
The median OS was 5.3 months in the group that received salvage chemotherapy and 3.8 months in the group that received best supportive care (HR, 0.657; P = .007).
There was no difference in median OS between docetaxel and irinotecan (5.2 months vs. 6.5 months, P = .116).[32][Level of evidence A1]
Sources: 32 · Level of evidence A1
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Ramucirumab is a fully humanized monoclonal antibody directed against the vascular endothelial growth factor receptor-2.
Evidence (ramucirumab):
The international, phase III, placebo-controlled, REGARD trial (NCT00917384) included 355 patients with stage IV gastric or gastroesophageal junction cancer who had progressed on a first-line 5-FU‒ or platinum-containing regimen. Patients were randomly assigned in a 2:1 fashion to receive either ramucirumab or placebo.[33]Ramucirumab is an acceptable treatment in patients with cisplatin- or 5-FU‒refractory, stage IV, gastric cancer.
The international, phase III, placebo-controlled, REGARD trial (NCT00917384) included 355 patients with stage IV gastric or gastroesophageal junction cancer who had progressed on a first-line 5-FU‒ or platinum-containing regimen. Patients were randomly assigned in a 2:1 fashion to receive either ramucirumab or placebo.[33]Ramucirumab is an acceptable treatment in patients with cisplatin- or 5-FU‒refractory, stage IV, gastric cancer.
Patients who were assigned to ramucirumab had a significantly improved median OS of 5.2 months compared with a median OS of 3.8 months in patients who were assigned to the placebo (HR, 0.776; P = .047).
Rates of hypertension were higher in the ramucirumab group than in the placebo group.[33][Level of evidence A1]
Sources: 33 · Level of evidence A1
In the international, double-blinded, phase III RAINBOW trial (NCT01170663), 665 patients were randomly assigned to receive paclitaxel (80 mg/m2) on days 1, 8, and 15 every 28 days with either ramucirumab (8 mg/kg) added on days 1 and 15 or a placebo added on days 1 and 15.[34]The combination of paclitaxel and ramucirumab is an acceptable second-line chemotherapy regimen in patients with stage IV gastric or gastroesophageal junction cancer.
In the international, double-blinded, phase III RAINBOW trial (NCT01170663), 665 patients were randomly assigned to receive paclitaxel (80 mg/m2) on days 1, 8, and 15 every 28 days with either ramucirumab (8 mg/kg) added on days 1 and 15 or a placebo added on days 1 and 15.[34]The combination of paclitaxel and ramucirumab is an acceptable second-line chemotherapy regimen in patients with stage IV gastric or gastroesophageal junction cancer.
Patients who were assigned to ramucirumab had a significant improvement in median OS of 9.6 months compared with a median OS of 7.4 months in patients who were assigned to a placebo (HR, 0.807; P = .017).
Grade 3 or higher neutropenia, fatigue, hypertension, and abdominal pain were more common in the ramucirumab group.[34][Level of evidence A1]
Sources: 34 · Level of evidence A1
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Evidence (pembrolizumab for patients with dMMR or MSI-H tumors):
In a phase II study of pembrolizumab 200 mg IV every 3 weeks in patients with colon cancer with or without dMMR, and noncolorectal cancer with dMMR, the immune-related objective response rate was 71% (5 of 7 patients). Based on these data, pembrolizumab was approved for patients with dMMR solid tumors that have progressed after previous treatment and who have no satisfactory alternative treatment options.[35]
Sources: 35
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Trastuzumab deruxtecan is an antibody-drug conjugate combining an anti-HER2 antibody with a topoisomerase I inhibitor via a cleavable tetrapeptide-based linker. The U.S. Food and Drug Administration (FDA) approved trastuzumab deruxtecan for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer that is HER2-positive who have previously received a trastuzumab-based regimen.
Evidence (trastuzumab deruxtecan for patients with HER2-positive tumors):
The international, open-label, randomized, phase II DESTINY-Gastric01 trial (NCT03329690) included 187 patients from Japan and South Korea with HER2-positive advanced gastric cancer that had progressed after at least two previous therapies (including trastuzumab). Patients were randomly assigned in a 2:1 ratio to receive either trastuzumab deruxtecan (6.4 mg/kg every 3 weeks) or the physician’s choice of chemotherapy. The primary study end point was objective response.[36]
Sources: DESTINY-Gastric01 · 36
The international, open-label, randomized, phase II DESTINY-Gastric01 trial (NCT03329690) included 187 patients from Japan and South Korea with HER2-positive advanced gastric cancer that had progressed after at least two previous therapies (including trastuzumab). Patients were randomly assigned in a 2:1 ratio to receive either trastuzumab deruxtecan (6.4 mg/kg every 3 weeks) or the physician’s choice of chemotherapy. The primary study end point was objective response.[36]
The objective response rate was 51% for patients who received trastuzumab deruxtecan and 14% for patients who received chemotherapy (P < .001).
The OS was 12.5 months for patients who received trastuzumab deruxtecan and 8.4 months for patients who received chemotherapy (HR, 0.59; 95% CI, 0.39–0.88, P = .02).[36][Level of evidence A1]
Sources: 36 · Level of evidence A1
Common side effects of trastuzumab deruxtecan included neutropenia (grade 3–4 in 51% of patients, with six patients developing neutropenic fever) and anemia (grade 3–4 in 38% of patients). Twelve patients (10%) developed drug-related interstitial lung disease.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Trifluridine and tipiracil is an oral cytotoxic therapy approved by the FDA for third-line treatment of patients with metastatic gastric or gastroesophageal junction cancer.
Evidence (trifluridine and tipiracil):
A randomized, double-blinded, placebo-controlled, international, phase III trial (TAGS [NCT02500043]) included 507 patients with metastatic gastric or gastroesophageal junction adenocarcinoma who had progressive disease after receiving two previous regimens, including a fluoropyrimidine, a platinum agent, and a taxane and/or irinotecan. Patients were randomly assigned in a 2:1 ratio to receive either trifluridine and tipiracil (35 mg/m2 twice a day on days 1−5 and 8−12 every 28 days) or placebo.[37]
A randomized, double-blinded, placebo-controlled, international, phase III trial (TAGS [NCT02500043]) included 507 patients with metastatic gastric or gastroesophageal junction adenocarcinoma who had progressive disease after receiving two previous regimens, including a fluoropyrimidine, a platinum agent, and a taxane and/or irinotecan. Patients were randomly assigned in a 2:1 ratio to receive either trifluridine and tipiracil (35 mg/m2 twice a day on days 1−5 and 8−12 every 28 days) or placebo.[37]
The median OS was 5.7 months (95% CI, 4.8−6.2) in patients who received trifluridine and tipiracil, compared with 3.6 months (95% CI, 3.1−4.1) in patients who received placebo (HR, 0.69; 95% CI, 0.57−0.85; P = .00058).
The objective response rate was 4% (disease control rate, 44%) in the trifluridine and tipiracil arm, compared with 2% (disease control rate, 14%) in the placebo arm.
Grade 3 or higher adverse events occurred in 80% of patients treated with trifluridine and tipiracil, compared with 58% of patients who received placebo.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
While pembrolizumab was previously evaluated as third-line treatment for patients with gastric and gastroesophageal junction cancers and a PD-L1 CPS of one or greater, this approval was withdrawn after updates to first-line therapy using combination chemotherapy and programmed death 1 (PD-1) inhibitors.
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Nivolumab has been approved by the Japanese Ministry of Health, Labor, and Welfare for treatment of advanced gastric cancer, regardless of PD-L1 CPS status.
Evidence (nivolumab):
A randomized, double-blinded, placebo-controlled, phase III trial (ONO-4538-12 [ATTRACTION-2] [NCT02267343]) enrolled 493 patients with refractory gastroesophageal/gastric cancer from Japan, South Korea, and Taiwan.[38] Patients were randomly assigned 2:1 to receive either nivolumab (3 mg/kg every 2 weeks) or placebo.
Sources: ONO-4538-12 · 38
A randomized, double-blinded, placebo-controlled, phase III trial (ONO-4538-12 [ATTRACTION-2] [NCT02267343]) enrolled 493 patients with refractory gastroesophageal/gastric cancer from Japan, South Korea, and Taiwan.[38] Patients were randomly assigned 2:1 to receive either nivolumab (3 mg/kg every 2 weeks) or placebo.
The median OS was 5.26 months (95% CI, 4.60–6.37) in the nivolumab group compared with 4.14 months (95% CI, 3.42–4.86) in the placebo group.
Serious treatment-related adverse events occurred in 10% of the patients.[38][Level of evidence A1]
Sources: 38 · Level of evidence A1
Source: Stomach Cancer Treatment, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Endoluminal laser therapy is a procedure in which an endoscope (a thin, lighted tube) with a laser attached is used as a knife to open a gastrointestinal blockage.
Source: Stomach Cancer Treatment, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Radiation therapy
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Stomach cancer is sometimes treated with external radiation therapy. This type of radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects
Source: Stomach Cancer Treatment, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Chemotherapy
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Chemotherapy for stomach cancer is usually systemic, meaning it is injected into a vein or given by mouth. When given this way, the drugs enter the bloodstream to reach cancer cells throughout the body.
Sources: injected
Chemotherapy drugs used to treat stomach cancer include:
capecitabine
Sources: capecitabine
cisplatin
Sources: cisplatin
docetaxel
Sources: docetaxel
doxorubicin
Sources: doxorubicin
epirubicin
Sources: epirubicin
fluorouracil (5-FU)
Sources: fluorouracil (5-FU)
irinotecan
Sources: irinotecan
leucovorin
Sources: leucovorin
oxaliplatin
Sources: oxaliplatin
paclitaxel
Sources: paclitaxel
trifluridine and tipiracil
Sources: trifluridine and tipiracil
To learn more about how chemotherapy works, how it is given, common side effects, and more, visit Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.
Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer
Source: Stomach Cancer Treatment, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Targeted therapy
Targeted therapy uses drugs or other substances to identify and attack specific cancer cells. Your doctor may suggest biomarker tests to help predict your response to certain targeted therapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Sources: biomarker · Biomarker Testing for Cancer Treatment
Targeted therapies used to treat stomach cancer include:
ramucirumab
Sources: ramucirumab
regorafenib
Sources: regorafenib
trastuzumab
Sources: trastuzumab
trastuzumab deruxtecan
Sources: trastuzumab deruxtecan
zolbetuximab
Sources: zolbetuximab
Learn more about Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Source: Stomach Cancer Treatment, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Immunotherapy
Immunotherapy helps a person’s immune system fight cancer. Your doctor may suggest biomarker tests to help predict your response to certain immunotherapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Sources: immune system · Biomarker Testing for Cancer Treatment
Immunotherapy drugs used to treat stomach cancer include:
nivolumab
Sources: nivolumab
pembrolizumab
Sources: pembrolizumab
These drugs work in more than one way to kill cancer cells. They are also considered targeted therapy because they target specific changes or substances in cancer cells.
Learn more about Immunotherapy to Treat Cancer and Immunotherapy Side Effects.
Sources: Immunotherapy to Treat Cancer · Immunotherapy Side Effects
Source: Stomach Cancer Treatment, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Hyperthermic intraperitoneal chemotherapy (HIPEC)
Regional chemotherapy is a method of placing chemotherapy directly into an organ or a body cavity, such as the abdomen, to mainly affect cancer cells in those areas.
A type of regional chemotherapy called hyperthermic intraperitoneal chemotherapy, or hot chemotherapy, is being studied to treat stomach cancer and may be offered at certain treatment centers. After the surgeon has removed as much of the cancer as possible during surgery, a chemotherapy drug, such as mitomycin or cisplatin, is warmed and pumped directly into the peritoneal cavity through a thin tube for about 2 hours. The surgeon then drains the chemotherapy from the abdomen and rinses the abdomen before closing the incision.
Sources: mitomycin · cisplatin · peritoneal cavity · incision
Gastric Cancer
ClinicalTrials.gov recordEsophageal Cancer, Gastric Cancer
ClinicalTrials.gov recordGastric Cancer
ClinicalTrials.gov recordStomach Neoplasms
ClinicalTrials.gov recordGastric Cancer, Adenocarcinoma
ClinicalTrials.gov recordGastric Cancer
ClinicalTrials.gov recordGastric Cancer
ClinicalTrials.gov recordGastric Cancer
ClinicalTrials.gov recordGastric Cancer
ClinicalTrials.gov recordGastric Cancer
ClinicalTrials.gov recordGastric Adenocarcinoma
ClinicalTrials.gov recordRefractory Metastatic Gastric Cancer
ClinicalTrials.gov recordNeoplasm, Gastrointestinal
ClinicalTrials.gov recordLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric...
ClinicalTrials.gov recordGastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
ClinicalTrials.gov recordLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric...
ClinicalTrials.gov recordStomach Neoplasms
ClinicalTrials.gov recordGastric, or Gastroesophageal Junction Adenocarcinoma
ClinicalTrials.gov recordGastrointestinal Neoplasms, Esophagogastric Junction
ClinicalTrials.gov record1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease...
1.5 HER2-Positive Locally Advanced or Metastatic Gastric Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or...
Gastric Cancer
1.3 Metastatic Gastric Cancer Herceptin is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction...
1.3 Metastatic Gastric Cancer HERZUMA is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction...
1.3 Metastatic Gastric Cancer KANJINTI is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction...
1.8 Gastric Cancer KEYTRUDA QLEX, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic...
1.10 Gastric Cancer KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive...
1.2 Metastatic Gastric Cancer LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a...
1.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction...
1.3 Metastatic Gastric Cancer Ontruzant is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction...
1.12 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with...
1.14 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or...
Treatment of Stage 0 Gastric Cancer
Treatment of Stage I Gastric Cancer
Treatment of Stage IV, Inoperable, and Recurrent Gastric Cancer
1.2 Gastric Cancer TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction...
1.3 Metastatic Gastric Cancer TRAZIMERA is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction...
TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal...
DailyMed label